COMP <GO>
COGT vs JNJ // GROSS PROFIT MARGIN
Cogent Biosciences Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: COGT 4
— JNJ 9
▲ GROSS PROFIT MARGIN LEADER: JNJ
LAST: $31.02 (-2.94%) • MKT CAP: $5.55B
gross-margins
41.00%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COGT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COGT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.80% | 2.97% | -7.77 | JNJ | /fcf-yield <GO> |
| Operating Margin | -21.50% | 34.70% | -56.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -21.20% | 28.50% | -49.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 22.00% | 6.00% | +16.00 | COGT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.84 | 5.59 | +5.25 | COGT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | COGT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.4 | 60.4 | -12.95 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.08 | -0.03 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 23.0x | -1.00 | COGT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.55B | $662.49B | -$656.95B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COGT REV | JNJ REV | COGT GROSS % | JNJ GROSS % | COGT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | -$266.0M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$208.4M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | -$153.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COGT // BETA 1.05
JNJ // BETA 1.08